We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Breast Cancer Diagnosis Uses Spatial Light Interference Microscopy

By LabMedica International staff writers
Posted on 16 Sep 2015
Print article
Image: A comparison of stained bright-field microscopy (top row) and SLIM (bottom row) images in their respective abilities to show malignant and benign. The images were obtained from adjacent sections. Color bars are in radians (Photo courtesy of Hassaan Majeed).
Image: A comparison of stained bright-field microscopy (top row) and SLIM (bottom row) images in their respective abilities to show malignant and benign. The images were obtained from adjacent sections. Color bars are in radians (Photo courtesy of Hassaan Majeed).
The standard practice in histopathology of breast cancers is to examine a hematoxylin and eosin (H&E) stained tissue biopsy under a microscope to diagnose whether a lesion is benign or malignant.

A new optical method called Spatial Light Interference Microscopy (SLIM) has been used to quickly and accurately determine whether breast tissue lesions are cancerous, as this quantitative, label-free, and high-throughput diagnosis method is highly advantageous.

Scientists at the University of Illinois (Urbana, IL, USA) used the breast tissue biopsies of 400 different patients, and selected two parallel, adjacent sections from each biopsy. One was stained and the other left unstained. The unstained samples were analyzed using a SLIM module attached to a commercial phase contrast microscope to generate interferograms, which are photographic images derived from data based on how the tissue refracts light.

Four interferograms were used to produce one quantitative image showing areas with different refractive properties in different colors. The boundary between tumors and the cells around them were clearly delineated, making it possible to assess whether the tumors were malignant or benign. As a first step toward quantitative diagnosis based on SLIM, the team carried out a qualitative evaluation of our label-free images. These images were shown to two pathologists who classified each case as either benign or malignant. This diagnosis was then compared against the diagnosis of the two pathologists on corresponding H&E stained tissue images and the number of agreements were counted.

The agreement between SLIM and H&E based diagnosis was 88% for the first pathologist and 87% for the second. The results demonstrate the potential and promise of SLIM for quantitative, label-free, and high-throughput diagnosis. YongKeun Park, PhD, a professor at Korean Advanced Institute of Science and Technology (Daejeon, Republic of Korea) and a guest editor of the of the special section on Quantitative Phase Imaging in Biomedicine in which the study appears said, “Conventional methods for diagnosis of breast cancer have several limitations, including observer discrepancy.” The study was published on August 20, 2015, in the Journal of Biomedical Optics.

Related Links:

University of Illinois 
Korean Advanced Institute of Science and Technology


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.